It is very uncertain whether higher changes CHD events: myocardial infarction (fatal or non‐fatal) or angina… compared with lower omega‐6: primary outcomes (very low certainty).
It is very uncertain whether higher changes MACCEs Study duration range 24‐96 months Omega‐6 dose range… compared with lower omega‐6: primary outcomes (very low certainty).
It is very uncertain whether higher changes stroke: fatal or non‐fatal Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
Higher showed no clear difference in MI Study duration range 12‐96 months Omega‐6 dose range 2.8%‐24.5% E compared with lower omega‐6: additional key outcomes (low certainty).
It is very uncertain whether higher changes all allergic disease ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes allergic rhinitis ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
Higher showed no clear difference in asthma ‐ infant incidence compared with lower PUFA intake (low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes allergic rhinitis ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).